Increased sensitivity of SARS-coronavirus to a combination of human type I and type II interferons.
Identifieur interne : 005694 ( Main/Merge ); précédent : 005693; suivant : 005695Increased sensitivity of SARS-coronavirus to a combination of human type I and type II interferons.
Auteurs : Carolina Scagnolari [Italie] ; Elisa Vicenzi ; Francesca Bellomi ; Maria Giuseppina Stillitano ; Debora Pinna ; Guido Poli ; Massimo Clementi ; Ferdinando Dianzani ; Guido AntonelliSource :
- Antiviral therapy [ 1359-6535 ] ; 2004.
Descripteurs français
- KwdFr :
- Animaux, Cellules Vero, Humains, Interféron de type I (génétique), Interféron de type I (pharmacologie), Interféron gamma (génétique), Interféron gamma (pharmacologie), Protéines G (génétique), Protéines G (métabolisme), Protéines de résistance aux myxovirus, Protéines recombinantes (pharmacologie), Réplication virale (), Synergie des médicaments, Virus du SRAS (), Virus du SRAS (physiologie).
- MESH :
- génétique : Interféron de type I, Interféron gamma, Protéines G.
- métabolisme : Protéines G.
- pharmacologie : Interféron de type I, Interféron gamma, Protéines recombinantes.
- physiologie : Virus du SRAS.
- Animaux, Cellules Vero, Humains, Protéines de résistance aux myxovirus, Réplication virale, Synergie des médicaments, Virus du SRAS.
English descriptors
- KwdEn :
- Animals, Chlorocebus aethiops, Drug Synergism, GTP-Binding Proteins (genetics), GTP-Binding Proteins (metabolism), Humans, Interferon Type I (genetics), Interferon Type I (pharmacology), Interferon-gamma (genetics), Interferon-gamma (pharmacology), Myxovirus Resistance Proteins, Recombinant Proteins (pharmacology), SARS Virus (drug effects), SARS Virus (physiology), Vero Cells, Virus Replication (drug effects).
- MESH :
- chemical , genetics : GTP-Binding Proteins, Interferon Type I, Interferon-gamma.
- chemical , metabolism : GTP-Binding Proteins.
- chemical , pharmacology : Interferon Type I, Interferon-gamma, Recombinant Proteins.
- drug effects : SARS Virus, Virus Replication.
- physiology : SARS Virus.
- Animals, Chlorocebus aethiops, Drug Synergism, Humans, Myxovirus Resistance Proteins, Vero Cells.
Abstract
There is currently an urgent need to identify effective antiviral agents that will prevent and treat severe acute respiratory syndrome coronavirus (SARS-CoV) infection. In this study, we have investigated and compared the antiviral effect of different interferons (IFNs) on SARS-CoV replication in the epithelial kidney monkey Vero cell line. The results showed that SARS-CoV grown in Vero cells is moderately sensitive to IFN-beta and only weakly sensitive to IFN-alpha and IFN-gamma, in comparison to other IFN-sensitive viruses, such as those for encephalomyocarditis, vesicular stomatitis and Newcastle disease. Simultaneous incubation of Vero cells with IFN-beta and IFN-gamma indicated that they may act synergistically against SARS-CoV replication. The IFN-induced MxA protein was detected in the IFN-treated Vero cells. The data, however, suggest that the antiviral activity of IFN against SARS-CoV virus is independent of MxA expression.
PubMed: 15651759
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 002937
- to stream PubMed, to step Curation: 002937
- to stream PubMed, to step Checkpoint: 002C40
- to stream Ncbi, to step Merge: 000D30
- to stream Ncbi, to step Curation: 000D30
- to stream Ncbi, to step Checkpoint: 000D30
Links to Exploration step
pubmed:15651759Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Increased sensitivity of SARS-coronavirus to a combination of human type I and type II interferons.</title><author><name sortKey="Scagnolari, Carolina" sort="Scagnolari, Carolina" uniqKey="Scagnolari C" first="Carolina" last="Scagnolari">Carolina Scagnolari</name><affiliation wicri:level="3"><nlm:affiliation>Department of Exerimental Medicine and Pathology--Virology section, University La Sapienza, Rome, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Exerimental Medicine and Pathology--Virology section, University La Sapienza, Rome</wicri:regionArea><placeName><settlement type="city">Rome</settlement><region nuts="2">Latium</region></placeName></affiliation></author><author><name sortKey="Vicenzi, Elisa" sort="Vicenzi, Elisa" uniqKey="Vicenzi E" first="Elisa" last="Vicenzi">Elisa Vicenzi</name></author><author><name sortKey="Bellomi, Francesca" sort="Bellomi, Francesca" uniqKey="Bellomi F" first="Francesca" last="Bellomi">Francesca Bellomi</name></author><author><name sortKey="Stillitano, Maria Giuseppina" sort="Stillitano, Maria Giuseppina" uniqKey="Stillitano M" first="Maria Giuseppina" last="Stillitano">Maria Giuseppina Stillitano</name></author><author><name sortKey="Pinna, Debora" sort="Pinna, Debora" uniqKey="Pinna D" first="Debora" last="Pinna">Debora Pinna</name></author><author><name sortKey="Poli, Guido" sort="Poli, Guido" uniqKey="Poli G" first="Guido" last="Poli">Guido Poli</name></author><author><name sortKey="Clementi, Massimo" sort="Clementi, Massimo" uniqKey="Clementi M" first="Massimo" last="Clementi">Massimo Clementi</name></author><author><name sortKey="Dianzani, Ferdinando" sort="Dianzani, Ferdinando" uniqKey="Dianzani F" first="Ferdinando" last="Dianzani">Ferdinando Dianzani</name></author><author><name sortKey="Antonelli, Guido" sort="Antonelli, Guido" uniqKey="Antonelli G" first="Guido" last="Antonelli">Guido Antonelli</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2004">2004</date><idno type="RBID">pubmed:15651759</idno><idno type="pmid">15651759</idno><idno type="wicri:Area/PubMed/Corpus">002937</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002937</idno><idno type="wicri:Area/PubMed/Curation">002937</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002937</idno><idno type="wicri:Area/PubMed/Checkpoint">002C40</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002C40</idno><idno type="wicri:Area/Ncbi/Merge">000D30</idno><idno type="wicri:Area/Ncbi/Curation">000D30</idno><idno type="wicri:Area/Ncbi/Checkpoint">000D30</idno><idno type="wicri:doubleKey">1359-6535:2004:Scagnolari C:increased:sensitivity:of</idno><idno type="wicri:Area/Main/Merge">005694</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Increased sensitivity of SARS-coronavirus to a combination of human type I and type II interferons.</title><author><name sortKey="Scagnolari, Carolina" sort="Scagnolari, Carolina" uniqKey="Scagnolari C" first="Carolina" last="Scagnolari">Carolina Scagnolari</name><affiliation wicri:level="3"><nlm:affiliation>Department of Exerimental Medicine and Pathology--Virology section, University La Sapienza, Rome, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Exerimental Medicine and Pathology--Virology section, University La Sapienza, Rome</wicri:regionArea><placeName><settlement type="city">Rome</settlement><region nuts="2">Latium</region></placeName></affiliation></author><author><name sortKey="Vicenzi, Elisa" sort="Vicenzi, Elisa" uniqKey="Vicenzi E" first="Elisa" last="Vicenzi">Elisa Vicenzi</name></author><author><name sortKey="Bellomi, Francesca" sort="Bellomi, Francesca" uniqKey="Bellomi F" first="Francesca" last="Bellomi">Francesca Bellomi</name></author><author><name sortKey="Stillitano, Maria Giuseppina" sort="Stillitano, Maria Giuseppina" uniqKey="Stillitano M" first="Maria Giuseppina" last="Stillitano">Maria Giuseppina Stillitano</name></author><author><name sortKey="Pinna, Debora" sort="Pinna, Debora" uniqKey="Pinna D" first="Debora" last="Pinna">Debora Pinna</name></author><author><name sortKey="Poli, Guido" sort="Poli, Guido" uniqKey="Poli G" first="Guido" last="Poli">Guido Poli</name></author><author><name sortKey="Clementi, Massimo" sort="Clementi, Massimo" uniqKey="Clementi M" first="Massimo" last="Clementi">Massimo Clementi</name></author><author><name sortKey="Dianzani, Ferdinando" sort="Dianzani, Ferdinando" uniqKey="Dianzani F" first="Ferdinando" last="Dianzani">Ferdinando Dianzani</name></author><author><name sortKey="Antonelli, Guido" sort="Antonelli, Guido" uniqKey="Antonelli G" first="Guido" last="Antonelli">Guido Antonelli</name></author></analytic><series><title level="j">Antiviral therapy</title><idno type="ISSN">1359-6535</idno><imprint><date when="2004" type="published">2004</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Chlorocebus aethiops</term><term>Drug Synergism</term><term>GTP-Binding Proteins (genetics)</term><term>GTP-Binding Proteins (metabolism)</term><term>Humans</term><term>Interferon Type I (genetics)</term><term>Interferon Type I (pharmacology)</term><term>Interferon-gamma (genetics)</term><term>Interferon-gamma (pharmacology)</term><term>Myxovirus Resistance Proteins</term><term>Recombinant Proteins (pharmacology)</term><term>SARS Virus (drug effects)</term><term>SARS Virus (physiology)</term><term>Vero Cells</term><term>Virus Replication (drug effects)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Cellules Vero</term><term>Humains</term><term>Interféron de type I (génétique)</term><term>Interféron de type I (pharmacologie)</term><term>Interféron gamma (génétique)</term><term>Interféron gamma (pharmacologie)</term><term>Protéines G (génétique)</term><term>Protéines G (métabolisme)</term><term>Protéines de résistance aux myxovirus</term><term>Protéines recombinantes (pharmacologie)</term><term>Réplication virale ()</term><term>Synergie des médicaments</term><term>Virus du SRAS ()</term><term>Virus du SRAS (physiologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>GTP-Binding Proteins</term><term>Interferon Type I</term><term>Interferon-gamma</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>GTP-Binding Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Interferon Type I</term><term>Interferon-gamma</term><term>Recombinant Proteins</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>SARS Virus</term><term>Virus Replication</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Interféron de type I</term><term>Interféron gamma</term><term>Protéines G</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Protéines G</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Interféron de type I</term><term>Interféron gamma</term><term>Protéines recombinantes</term></keywords><keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Chlorocebus aethiops</term><term>Drug Synergism</term><term>Humans</term><term>Myxovirus Resistance Proteins</term><term>Vero Cells</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Cellules Vero</term><term>Humains</term><term>Protéines de résistance aux myxovirus</term><term>Réplication virale</term><term>Synergie des médicaments</term><term>Virus du SRAS</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">There is currently an urgent need to identify effective antiviral agents that will prevent and treat severe acute respiratory syndrome coronavirus (SARS-CoV) infection. In this study, we have investigated and compared the antiviral effect of different interferons (IFNs) on SARS-CoV replication in the epithelial kidney monkey Vero cell line. The results showed that SARS-CoV grown in Vero cells is moderately sensitive to IFN-beta and only weakly sensitive to IFN-alpha and IFN-gamma, in comparison to other IFN-sensitive viruses, such as those for encephalomyocarditis, vesicular stomatitis and Newcastle disease. Simultaneous incubation of Vero cells with IFN-beta and IFN-gamma indicated that they may act synergistically against SARS-CoV replication. The IFN-induced MxA protein was detected in the IFN-treated Vero cells. The data, however, suggest that the antiviral activity of IFN against SARS-CoV virus is independent of MxA expression.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005694 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 005694 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Main
|étape= Merge
|type= RBID
|clé= pubmed:15651759
|texte= Increased sensitivity of SARS-coronavirus to a combination of human type I and type II interferons.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Merge/RBID.i -Sk "pubmed:15651759" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Merge/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |